Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NanoViricides has announced that the preliminary animal trials of HivCide-I, the company's proposed HIV therapeutic, will begin soon at a BSL-3 facility in Boston, Massachusetts.
Subscribe to our email newsletter
The initial results are expected by the second week of May, 2008. These animal studies will be conducted by Krishna Menon, a world-renowned authority in preclinical and toxicological studies of novel therapeutics.
Anil Diwan, president of NanoViricides, said: “This is a proof of principle study and will be expanded further with a larger follow-up study to be performed at a major government research institution later in the year.”